Exploratory Study Comparing ClearSight System 2D Map to Post Surgery Histopathological Analysis in Lumpectomy

Clear Cut Medical Ltd.220 enrolled

Overview

Prospective, single-arm, multicenter, open label, non-randomized exploratory clinical study comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.

This study is a multicenter, non-randomized, cross-sectional comparative exploratory study comparing the ClearSight System 2D map results to post surgery histopathological analysis of excised mass in lumpectomy surgery. The Efficacy Objective is to assess the ability of the ClearSight™ System to detect malignant tissue less than or equal to 1 mm of margins of excised breast specimen in breast conserving surgery using histopathological assessment as reference. The Safety Objective is that all adverse events, serious adverse events (SAE) will be reported according to local regulations. The actual reporting is discussed in section 0. No device-related adverse events are expected. For more information please refer to the Investigator Brochure.

Study Type

OBSERVATIONAL

Enrollment

220

Conditions

Breast Cancer

Interventions

ClearSight™ SystemDEVICE

comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Women histologically diagnosed with carcinoma of the breast, scheduled for primary lumpectomy (partial mastectomy) procedure. 2. Age ≥18. 3. Signed ICF Exclusion Criteria: 1. Prior surgical procedure in the same breast within 12 months prior to the surgery date. 2. Recurrent breast cancer surgery. 3. Neoadjuvant chemotherapy. 4. Previous radiation therapy to the operated breast. 5. Pregnant / breast feeding. 6. Participating in any other study that might affect results.

Locations (5)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

The George Washington University Hospital (GWU)

Washington D.C., District of Columbia, United States

Kaplan Medical Center

Rehovot, Israel

Assuta Medical Center

Tel Aviv, Israel

Outcomes

Primary Outcomes

Malignant and non-malignant breast tissues will be assessed by ClearSight™ to detect malignant tissue less than or equal to 1 mm of margins of excised breast specimen in breast conserving surgery using histopathological assessment as reference

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.